- Market Capitalization, $K 1,119,616
- Shares Outstanding, K 37,571
- Annual Sales, $ 0 K
- Annual Income, $ -100,780 K
- 60-Month Beta 0.56
- Price/Sales N/A
- Price/Cash Flow N/A
- Price/Book 7.32
|Period||Period Low||Period High||Performance|
| || |
+21.69 (+175.49%)since 08/30/22
| || |
+24.60 (+260.32%)since 06/30/22
| || |
+11.70 (+52.35%)since 09/30/21
Altimmune (ALT) reports positive top-line results from its 12-week phase I study evaluating pemvidutide in patients with non-alcoholic fatty liver disease. The results fail to impress investors.
September S&P 500 futures (ESU22) are moderately up +0.03% this morning after three major US benchmark indices bounced back during the regular session as an on-target inflation report mainly stopped the...
Regulatory and pipeline updates from BMY and REGN are the key highlights from the biotech sector during the past week.
Akero Therapeutics (AKRO) reports positive top-line data from a mid-stage study evaluating its lead candidate, efruxifermin (EFX), in patients with NASH, fibrosis stage 2 or 3 (F2-F3). Stock up.
September S&P 500 futures (ESU22) are trending up +0.66% this morning after three major US benchmark indices veered sharply lower, marking their biggest single-day percentage declines since June 2020.
Akero Therapeutics, Inc. (NASDAQ: AKRO) is engaged as a clinical-stage biotechnology company that is focused on the research and development
The biotech's experimental NASH drug hit the mark in a key phase 2b trial.
As the connected fitness equipment maker keeps going through turmoil, good news helped lift a largely unknown company's share price.
Akero Therapeutics (AKRO) announces positive data from third cohort of its mid-stage study evaluating efruxifermin (EFX) in NASH. Stock up.
SOUTH SAN FRANCISCO, Calif., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing...
|Akero Therapeutics Inc|
|Bioshares Biotech Clinical Trial|
|Alps Medical Breakthroughs ETF|
|SSGA US Smallcap Low Vol Index SPDR|
|Micro-Cap Ishares ETF|
|Principal Healthcare Innovators Index|
|3rd Resistance Point||42.07|
|2nd Resistance Point||38.72|
|1st Resistance Point||36.39|
|1st Support Level||30.71|
|2nd Support Level||27.36|
|3rd Support Level||25.03|